Table 3.

Treatment effect on iOR, cOR and ETS: rates by treatment arms and odds ratios estimated through bivariate and multivariate logistic regressions with treatment and miR-31-3p expression level as covariates

Response rates (total number of patients)
EndpointmiR-pop expression group (n)aUnivariate OR [95% CI] P valueMultivariate OR [95% CI] P value (adjusted for)miR-pop group by treatment interaction test P value (adjusted for)FOLFIRI + bevacizumabFOLFIRI + cetuximab
iORHigh (n = 104)1.4 [0.6–3.0]1.3 [0.6–2.9]P = 0.02 (4)55.8% (52)63.5% (52)
P = 0.42P = 0.57 (1)
Low (n = 202)3.9 [1.9–8.0]4.0 [1.9–8.2]62.5% (112)86.7% (90)
P < 0.01P < 0.01 (2)
cORHigh (n = 98)0.9 [0.4–2.0]0.8 [0.3–1.9]P < 0.01 (1)55.3% (47)52.9% (51)
P = 0.81P = 0.56 (1)
Low (n = 181)5.0 [2.4–10.4]4.9 [2.3–10.5]54.8% (104)85.7% (77)
P < 0.01P < 0.01 (2)
ETS (6 weeks)High (n = 98)1.4 [0.6–3.4]1.3 [0.5–3.2]P = 0.04 (4)27.7% (47)35.3% (51)
P = 0.42P = 0.60 (1)
Low (n = 181)3.8 [2.0–7.1]4.0 [2.1–7.7]25.0% (104)55.8% (77)
P < 0.01P < 0.01 (3)
  • NOTE: Multivariate analysis adjusted for (i) BRAF mutational status and ECOG score (ii) ECOG score (iii) number of metastatic sites (iv) BRAF mutational status number of metastatic sites and ECOG score in the multivariate model. Patients with missing response were excluded.

  • aPatients with missing response were excluded.